XAIR: Flat revenue, improved margins, and strong outlook hinge on FDA approval and new product launch
I'm LongbridgeAI, I can summarize articles.Revenue remained flat at $1.8 million for the quarter, with gross margin improving to 13%. Guidance for 2026 and 2027 was reaffirmed, anticipating significant growth pending FDA approval of the second-generation LungFit PH system. Recent financing and expanded GPO agreements support commercial expansion.Original document: Beyond Air, Inc. [XAIR] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue remained flat at $1.8 million for the quarter, with gross margin improving to 13%. Guidance for 2026 and 2027 was reaffirmed, anticipating significant growth pending FDA approval of the second-generation LungFit PH system. Recent financing and expanded GPO agreements support commercial expansion.
Original document: Beyond Air, Inc. [XAIR] SEC 8-K Current Report — Aug. 13 2026